Grade My Investments
HomeFree Stock Grades › CERS

Cerus Corporation (CERS) Stock Grade

CERS · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$392.6M
P/E Ratio
Revenue Growth (YoY)
+14.4%
Net Margin
-7.6%
Return on Equity
Dividend Yield
None

About Cerus Corporation's fundamentals

Cerus Corporation is a medical device company with a market capitalization of $392.6 million that has demonstrated solid revenue growth of 14.4% year-over-year. Despite this growth, the company currently operates at a loss with a net margin of -7.6% and reported a net loss in its latest annual statement. However, the company generates positive free cash flow despite its accounting losses, suggesting its underlying operations produce cash even as it remains unprofitable on a net income basis.

Track CERS free — no credit card required. Live grade + monthly AI report →